In this study an attempt was made to establish the significance of a battery of molecular alterations and thereby identify risk predictors in oral carcinogenesis. For this purpose, EGFR, Stat3, H-ras, c-myc, p53, cyclin D1, p16, Rb, Ki-67 and Bcl-2 were localized immunohistochemically in normal mucosa (n=12), hyperplasia (n=35), dysplasia (n=25), early stage carcinoma (n=65) and advanced stage carcinoma (n=70). Deregulation occurred at an early stage and the number of alterations increased with disease progression. Using multivariate logistic regression analysis, the significant risk predictor for hyperplasia from normal mucosa was Ki-67 (OR=5.75, p=0.021); the significant risk predictors for dysplasia from hyperplasia were EGFR (OR=12.96, p=0.002), Stat3 (OR=17.16, p=0.0001), p16 (OR=5.50, p=0.039) and c-myc (OR=5.99, p=0.052); the significant risk predictors for early stage carcinoma from dysplasia were p53 (OR=6.63, p=0.0001) and Rb (OR=3.81, p=0.056); and the significant risk predictors for further progression were EGFR (OR=5.50, p=0.0001), Stat3 (OR=4.49, p=0.0001), H-ras (OR=4.05, p=0.001) and c-myc (OR=2.99, p=0.015). Cyclin D1 holds a key position linking upstream signaling pathways to cell cycle regulation. Gene products of the mitogenic signaling pathway play an equally significant role as cell cycle regulatory proteins in the hyperplasia-dysplasia-early-advanced-carcinoma sequence and together may provide a reference panel of markers for use in defining premalignant lesions and predicting the risk of malignant transformation and tumor progression.
Carlos de VicenteJ., Herrero-ZapateroA., FresnoM.F., LopezarranzJ.S.. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance.Oral Oncol2002; 38: 301–8.
2.
NevilleB.W., DayT.A.. Oral cancer and precancerous lesions.CA Cancer J Clin2002; 52: 195–215.
3.
NagpalJ.K., DasB.R.. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management.Oral Oncol2003; 39: 213–21.
4.
ReibelJ.. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological and molecular biological characteristics.Crit Rev Oral Biol Med2003; 14: 47–62.
5.
SudboJ., BryneM., MaoL.. Molecular based treatment of oral cancer.Oral Oncol2003; 39: 749–58.
6.
LiuS.C., Klein-SzantoA.J.. Markers of proliferation in normal and leukoplakic oral epithelia.Oral Oncol2000; 36: 145–51.
7.
RosinM.P., ChengX., PohC.. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.Clin Cancer Res2000; 6: 357–62.
8.
FearonE.R., VogelsteinB.. A genetic model for colorectal tumorigenesis.Cell1990; 61: 759–67.
9.
CalifanoJ., RietP., WestraW.. Genetic progression model for head and neck cancer: implications for field cancerization.Cancer Res1996; 56: 2488–92.
10.
RalhanR.. Molecular markers in cancer. In: PandeyM., NairM.K., SebastianP., eds. Advances in cancer.New Delhi: Jaypee Brothers Medical Publishers,1999; 1: 18–58.
11.
CalifanoJ., WestraW.H., MeiningerG., CorioR., KochW.M., SidranskyD.. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions.Clin Cancer Res2000; 6: 347–52.
12.
AktasH., CaiH., CooperG.M.. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.Mol Cell Biol1997; 17: 3850–7.
13.
AranyI., ChenS.H., MegyesiJ.K.. Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck.Cancer Lett2003; 199: 83–9.
14.
BowmenT., GarciaR., JoveR.. STATs in oncogenesis.Oncogene2000; 19: 2474–88.
15.
MasudaM., SuzuiM., YasumatuR.. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.Cancer Res2002; 62: 3351–5.
16.
NagpalJ.K., MishraR., DasB.R.. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis.Cancer2002; 94: 2393–400.
17.
FacchiniL.M., PennL.Z.. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights.FASEB J1998; 12: 633–51.
18.
EversoleL.R., SappJ.P.. c-myc oncoprotein expression in oral precancerous and early cancer lesions.Oral Oncol, Eur J Cancer1993; 29B: 131–5.
19.
BaralR.N., PatnaikS., DasB.R.. Co-expression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India.Eur J Oral Sci1998; 106: 907–13.
20.
PeeperD.S., UptonT.M., LadhaM.H.. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein.Nature1997; 386: 177–81.
21.
SchoelchM.L., RegeziJ.A., DekkerN.P.. Cell cycle proteins and the development of oral squamous cell carcinoma.Oral Oncol1999; 35: 333–42.
22.
RegeziJ.A., JordanR.C.. Oral cancer in the molecular age.J Calif Dent Assoc2001; 29: 578–84.
23.
RajuB., MehrotraR., OijordsbakkenG., Al-SharabiA.K., VasstrandE.N., IbrahimS.O.. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters.Anticancer Res2005; 25: 4699–706.
24.
StellerH.. Mechanisms and genes of cellular suicide.Science1995; 267: 1445–9.
25.
SulkowskaM., FamulskiW., ChyczewskiL., SulkowskiS.. Evaluation of p53 and Bcl-2 oncoprotein expression in precancerous lesions of the oral cavity.Neoplasma2001; 48: 94–8.
26.
TeniT., PawarS., SanghviV., SaranathD.. Expression of Bcl-2 and Bax in chewing tobacco-induced oral cancers and oral lesions from India.Pathol Oncol Res2002; 8: 109–14.
ShahN.G., TrivediT.I., TankshaliR.A.. Stat3 expression in oral squamous cell carcinoma: Association with clinicopathological parameters and survival.Int J Biol Markers2006; 21: 175–83.
29.
KannanS., JagadeeshC.G., RaveendranP.K.. Expression of p53 in leukoplakia and squamous cell carcinoma of the oral mucosa: correlation with expression of Ki67.J Clin Pathol: Mol Pathol1996; 49: M170–5.
30.
de PaulaA.M., CarvalhaisJ.N., DominguesM.G., BarretoD.C., MesquitaR.A.. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation.J Oral Pathol Med2000; 29: 477–82.
31.
FordA.C., GrandisJ.R.. Targeting epidermal growth factor receptor in head and neck cancer.Head Neck2003; 25: 67–73.
32.
SrinivasanM., JewellS.D.. Quantitative estimation of PCNA, c-myc, EGFR and TGF-alpha in oral submucous fibrosis–an immunohistochemical study.Oral Oncol2001; 37: 461–7.
33.
KalyankrishnaS., GrandisJ.R.. Epidermal growth factor receptor biology in head and neck cancer.J Clin Oncol2006; 24: 2666–72.
34.
TurksonJ.. STAT proteins as novel targets for cancer drug discovery.Expert Opin Ther Targets2004; 8: 409–22.
35.
BrombergJ.. Stat proteins and oncogenesis.J Clin Invest2002; 109: 1139–42.
36.
BrombergJ.F., WrzeszczynskaM.H., DevganG.. Stat3 as an oncogene.Cell1999; 98: 295–303.
37.
Catlett-FalconeR., LandowskiT.H., OshiroM.M.. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.Immunity1999; 10: 105–15.
38.
GrandisJ.R., DrenningS.D., ZengQ.. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.Proc Natl Acad Sci USA2000; 97: 4227–32.
39.
KlosekS.K., NakashiroK.I., HaraS., LiC., ShintaniS., HamakavaH.. Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma.Oncol Reports2004; 12: 293–6.
40.
ChanK.S., SanoS., KiguchiK.. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.J Clin Invest2004; 114: 720–8.
41.
SongJ.I., GrandisJ.R.. STAT signaling in head and neck cancer.Oncogene2000; 19: 2489–95.
42.
SierraA., LloverasB., CastellsagueX., MorenoL., Garcia-RamirezM., FabraA.. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma.Int J Cancer1995; 60: 54–60.
43.
SathyanK.M., NalinakumariK.R., KannanS.. Molecular profiling of cyclin D1 gene in oral carcinoma, a promising candidate for targeted therapy. XVIII Kerala Science Congress, CESS, Thiruvananthapuram 2006: 484–6.
44.
YuQ., GengY., SicinskiP.. Specific protection against breast cancers by cyclin D1 ablation.Nature2001; 411: 1017–21.
45.
SerranoM., LinA.W., McCurrachM.E., BeachD., LoweS.W.. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.Cell1997; 88: 593–602.
46.
PiatelliA., RubiniC., FioroniM., IezziG., SantinelliA.. Prevalence of p53, bcl-2 and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in pre-malignant and malignant lesions of the oral cavity.J Oral Maxillofac Surg2002; 60: 532–40.
47.
BoyleJ.O., HakimJ., KochW.. The incidence of p53 mutations increases with progression of head and neck cancer.Cancer Res1993; 53: 4477–80.
48.
EilersM., PicardD., YamamotoK.R., BishopJ.M.. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells.Nature1989; 340: 66–8.
49.
HeikkilaR., SchwabG., WickstromE.. A c-myc anti-sense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1.Nature1987; 328: 445–9.
50.
WatersC.M., LittlewoodT.D., HancockD.C., MooreJ.P., EvanG.I.. c-myc protein expression in untransformed fibroblasts.Oncogene1991; 5: 797–805.
51.
DiogeneH.R., TetuB., MorencyR., FortinA., MonteilR.A.. p53 overexpression in head and neck squamous cell carcinoma: review of the literature.Oral Oncol, Eur J Cancer1996; 32B: 143–9.
52.
HasinaR., LingenM.W.. Head and neck cancer: the pursuit of molecular diagnostic markers.Semin Oncol2004; 31: 718–25.
53.
ShinD.M., KimJ., RoJ.Y.. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis.Cancer Res1994; 54: 321–6.
54.
BovaR.J., QuinnD.I., NankervisJ.S.. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.Clin Cancer Res1999; 5: 2810–9.
55.
SoniS., KaurJ., KumarA.. Alterations of Rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.Oncology2005; 68: 314–25.
